Skip to main content Skip to navigation


 select-d png

Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism


Trial Design:

Prospective, randomised, open label, multicentre pilot study comparing dalteparin vs. rivoraxaban with a second placebo-controlled randomisation comparing the duration of anticoagulation therapy (6 months vs 12 months treatment) in Residual Vein Thrombosis [RVT] positive (+ve) patients.

Trial Status:

The select-d trial has closed to recruitment and is now in the follow-up phase.

The first randomisation closed on 22/12/2016 and the second randomisation closed on 28/02/2017.


NRCN Logo bayer.jpgscience City Logo UKCRC Logo

For trial related queries, please contact:
Chief Investigator
Prof. Annie Young annie dot young at warwick dot ac dot uk

Trial Coordinator
Cat Hill
catherine dot hill at warwick dot ac dot uk

Trial Administrator
Dharmesh Patel
D dot K dot Patel at warwick dot ac dot uk